Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response

2017151 citationsJournal Articlehybrid Open Access

Authors

Jan‐Patrick Stellmann · Universität Hamburg

Markus Krumbholz · Hertie Institute for Clinical Brain Research

Tim Friede · Universitätsmedizin Göttingen

Anna Gahlen · Ruhr University Bochum

Nadja Borisow · Max Delbrück Center

Katrin Fischer · Klinikum Görlitz

Kerstin Hellwig ·

Abstract

Age, antibody status and possibly previous attacks predict further attacks in patients treated for NMOSD. Azathioprine and rituximab are superior to interferon-β.

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Neurology Neurosurgery & Psychiatry

Volume 88, Issue 8, pp. 639-647

DOI: 10.1136/jnnp-2017-315603

Field-Weighted Citation Impact: 12.78